References
- Colbert GB, Patel D, Lerma EV. Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol. 2020 June 8:1–8 [Epub ahead of print. DOI:https://doi.org/10.1080/17512433.2020.1774363
- Lokelma® (sodium zirconium cyclosilicate) for oral suspension. US prescribing information [Internet]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; [cited 2020 July 30]. Available from: https://www.azpicentral.com/lokelma/lokelma.pdf
- Lokelma 5 g and 10 g powder for oral suspension: EU summary of product characteristics. AstraZeneca AB; 2020. [cited 2020 July 30]. Available from: https://www.ema.europa.eu/en/documents/product-information/lokelma-epar-product-information_en.pdf.
- Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015;88(2):404–411.
- Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223–2233.
- Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798–809.
- Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE. Am J Nephrol. 2019;50(6):473–480.
- Roger SD, Lavin PT, Lerma EV, et al. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, phase 3 study. Nephrol Dial Transplant. 2020. DOI:https://doi.org/10.1093/ndt/gfz285
- Bushinsky DA, Rossignol P, Spiegel DM, et al. Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis. Am J Nephrol. 2016;44(5):404–410.
- Fishbane S, Ford M, Fukagawa M, et al. A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia. J Am Soc Nephrol. 2019;30(9):1723–1733.
- Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372(3):222–231.